219 related articles for article (PubMed ID: 20858979)
21. Oatp1a4 and an L-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-β peptide.
Do TM; Bedussi B; Chasseigneaux S; Dodacki A; Yapo C; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2013; 36(3):555-61. PubMed ID: 23635403
[TBL] [Abstract][Full Text] [Related]
22. The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease.
Wan W; Chen H; Li Y
Int J Neurosci; 2014 Feb; 124(2):75-81. PubMed ID: 23855502
[TBL] [Abstract][Full Text] [Related]
23. Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier.
Bachmeier C; Beaulieu-Abdelahad D; Mullan M; Paris D
Mol Cell Neurosci; 2013 Sep; 56():255-62. PubMed ID: 23831388
[TBL] [Abstract][Full Text] [Related]
24. Increased efflux of amyloid-β peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis.
Paganetti P; Antoniello K; Devraj K; Toni N; Kieran D; Madani R; Pihlgren M; Adolfsson O; Froestl W; Schrattenholz A; Liebner S; Havas D; Windisch M; Cirrito JR; Pfeifer A; Muhs A
J Alzheimers Dis; 2014; 38(4):767-86. PubMed ID: 24072071
[TBL] [Abstract][Full Text] [Related]
25. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
26. Protection of the blood-brain barrier by pentosan against amyloid-β-induced toxicity.
Deli MA; Veszelka S; Csiszár B; Tóth A; Kittel A; Csete M; Sipos A; Szalai A; Fülöp L; Penke B; Abrahám CS; Niwa M
J Alzheimers Dis; 2010; 22(3):777-94. PubMed ID: 20847411
[TBL] [Abstract][Full Text] [Related]
27. An investigation into the role of P-glycoprotein in Alzheimer's disease lesion pathogenesis.
Jeynes B; Provias J
Neurosci Lett; 2011 Jan; 487(3):389-93. PubMed ID: 21047545
[TBL] [Abstract][Full Text] [Related]
28. Serum-derived immunoglobulins neutralize adverse effects of amyloid-beta peptide on the integrity of a blood-brain barrier in vitro model.
Poetsch V; Neuhaus W; Noe CR
J Alzheimers Dis; 2010; 21(1):303-14. PubMed ID: 20421696
[TBL] [Abstract][Full Text] [Related]
29. [Blood-brain barrier and Alzheimer's disease].
Kuwahara H; Nishida Y; Yokota T
Brain Nerve; 2013 Feb; 65(2):145-51. PubMed ID: 23399672
[TBL] [Abstract][Full Text] [Related]
30. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.
Bates KA; Verdile G; Li QX; Ames D; Hudson P; Masters CL; Martins RN
Mol Psychiatry; 2009 May; 14(5):469-86. PubMed ID: 18794889
[TBL] [Abstract][Full Text] [Related]
31. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta.
Tai LM; Loughlin AJ; Male DK; Romero IA
J Cereb Blood Flow Metab; 2009 Jun; 29(6):1079-83. PubMed ID: 19367293
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
Donahue JE; Johanson CE
J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
[TBL] [Abstract][Full Text] [Related]
33. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.
Qosa H; Abuasal BS; Romero IA; Weksler B; Couraud PO; Keller JN; Kaddoumi A
Neuropharmacology; 2014 Apr; 79():668-78. PubMed ID: 24467845
[TBL] [Abstract][Full Text] [Related]
34. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.
Kuhnke D; Jedlitschky G; Grube M; Krohn M; Jucker M; Mosyagin I; Cascorbi I; Walker LC; Kroemer HK; Warzok RW; Vogelgesang S
Brain Pathol; 2007 Oct; 17(4):347-53. PubMed ID: 17610523
[TBL] [Abstract][Full Text] [Related]
35. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
36. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
[TBL] [Abstract][Full Text] [Related]
37. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism.
Chikhale EG; Burton PS; Borchardt RT
J Pharmacol Exp Ther; 1995 Apr; 273(1):298-303. PubMed ID: 7714780
[TBL] [Abstract][Full Text] [Related]
38. Influence of P-glycoprotein on brucine transport at the in vitro blood-brain barrier.
Xu DH; Yan M; Li HD; Fang PF; Liu YW
Eur J Pharmacol; 2012 Sep; 690(1-3):68-76. PubMed ID: 22749978
[TBL] [Abstract][Full Text] [Related]
39. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier.
Ito S; Ohtsuki S; Terasaki T
Neurosci Res; 2006 Nov; 56(3):246-52. PubMed ID: 16926058
[TBL] [Abstract][Full Text] [Related]
40. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease.
Jaeger LB; Dohgu S; Sultana R; Lynch JL; Owen JB; Erickson MA; Shah GN; Price TO; Fleegal-Demotta MA; Butterfield DA; Banks WA
Brain Behav Immun; 2009 May; 23(4):507-17. PubMed ID: 19486646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
